Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners

Health and Quality of Life Outcomes

Ian CK Wong¹  Philip Asherson⁵  Paul Hodgkins²  Macey Murray³  Lynda Wilton³  Suzanne McCarthy⁴ 

[1] Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong;Shire Pharmaceuticals LLC, Wayne, Pennsylvania, USA;Centre for Paediatric Pharmacy Research, School of Pharmacy, University College London, London, UK;Pharmacy Department, Cork University Hospital, Cork, Ireland;MRC Social Genetic and Developmental Psychiatry, King’s College London, Institute of Psychiatry, London, UK

关键词: General practitioner;    Primary care;    Stimulant;    Adult;    Attention deficit hyperactivity disorder;   

Others  :  824013
DOI  :  10.1186/1477-7525-11-22

 received in 2012-08-27, accepted in 2013-02-05,  发布年份 2013

【 摘 要 】

Background

Compared to existing literature on childhood attention deficit hyperactivity disorder (ADHD), little published adult data are available, particularly outside of the United States. Using General Practitioner (GP) questionnaires from the United Kingdom, this study aimed to examine a number of issues related to ADHD in adults, across three cohorts of patients, adults who received ADHD drug treatment in childhood/adolescence but stopped prior to adulthood; adults who received ADHD drug treatment in childhood/adolescence and continued treatment into adulthood and adults who started ADHD drug treatment in adulthood.

Methods

Patients with a diagnosis of ADHD and prescribed methylphenidate, dexamfetamine or atomoxetine were identified using data from The Health Improvement Network (THIN). Dates when these drugs started and stopped were used to classify patients into the three cohorts. From each cohort, 50 patients were randomly selected and questionnaires were sent via THIN to their GPs.

GPs returned completed questionnaires to THIN who forwarded anonymised copies to the researchers. Datasets were analysed using descriptive statistics.

Results

Overall response rate was 89% (133/150). GPs stated that in 19 cases, the patient did not meet the criteria of that group; the number of valid questionnaires returned was 114 (76%). The following broad trends were observed: 1) GPs were not aware of the reason for treatment cessation in 43% of cases, 2) patient choice was the most common reason for discontinuation (56%), 3) 7% of patients who stopped pharmacological treatment subsequently reported experiencing ADHD symptoms, 4) 58% of patients who started pharmacological treatment for ADHD in adulthood received pharmacological treatment for other mental health conditions prior to the ADHD being diagnosed.

Conclusion

This study presents some key findings relating to ADHD; GPs were often not aware of the reason for patients stopping ADHD treatment in childhood or adolescence. Patient choice was identified as the most common reason for treatment cessation. For patients who started pharmacological treatment in adulthood, many patients received pharmacological treatment for comorbidities before a diagnosis of ADHD was made.

【 授权许可】

   
2013 McCarthy et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Clarke S, Heussler H, Kohn MR: Attention deficit disorder: not just for children. Intern Med J 2005, 35(12):721-725.
• [2]Hill JC, Schoener EP: Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996, 153(9):1143-1146.
• [3]Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. http://www.nice.org.uk/CG72 webcite
• [4]Faraone SV, Biederman J, Mick E: The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006, 36(2):159-165.
• [5]Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M: European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010, 10:67. BioMed Central Full Text
• [6]McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T: Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009, 194(3):273-277.
• [7]Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C: Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study. Health Technol Assess 2009, 13(50):iii-iv, ix-xi-1–120.
• [8]Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE: Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000, 48(1):9-20.
• [9]Skirrow C, McLoughlin G, Kuntsi J, Asherson P: Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurother 2009, 9(4):489-503.
• [10]Rosler M, Casas M, Konofal E, Buitelaar J: Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 2010, 11(5):684-698.
• [11]Asherson P: Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005, 5(4):525-539.
• [12]Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C: Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007, 190:402-409.
• [13]Simon V, Czobor P, Balint S, Meszaros A, Bitter I: Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009, 194(3):204-211.
• [14]Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Technology Appraisal 98. http://www.nice.org.uk/TA98 webcite
• [15]Mental health of children and young people in Great Britain. 2004. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_4118332 webcite
• [16]McBride D, Hardoon S, Walters K, Gilmour S, Raine R: Explaining variation in referral from primary to secondary care: cohort study. BMJ 2010, 341:c6267.
• [17]Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD: Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2009, 18(8):730-736.
• [18]Lo Re V 3rd, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD: Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009, 18(9):807-814.
• [19]Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL: Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007, 16(4):393-401.
• [20]McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC: The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr 2012, 12(1):78. BioMed Central Full Text
• [21]McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC: Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry 2012, 12(1):219. BioMed Central Full Text
• [22]Ruigomez A, Martin-Merino E, Rodriguez LA: Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf 2010, 19(6):579-585.
• [23]Sibbald B, Addington-Hall J, Brenneman D, Freeling P: Telephone versus postal surveys of general practitioners: methodological considerations. Br J Gen Pract 1994, 44(384):297-300.
• [24]Barkley RA, Murphy KR, Fischer M: ADHD in Adults: What the Science Says. New York, NY: Guilford Press; 2008.
• [25]Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011, 20(1):17-37.
• [26]McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC: Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009, 32(11):1089-1096.
• [27]National Service Framework for Children, Young People and Maternity Services. Transition: Getting it Right for Young People. Improving the Transition of Young People with Long-Term Conditions from Children’s to Adult Health Services. UK. http://www.dh.gov.uk/assetRoot/04/13/21/49/04132149.pdf webcite
• [28]Asherson P, Chen W, Craddock B, Taylor E: Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 2007, 190:4-5.
• [29]ADHD - Services Over Scotland. Report of the Service Profiling Exercise. http://www.healthcareimprovementscotland.org/programmes/mental_health/adhd/adhd_service_profile.aspx webcite
• [30]Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Dopfner M: Nonpharmacological interventions for adhd: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013, AiA:1-15.
• [31]Asherson P, Akehurst R, Kooij JJ, Huss M, Beusterien K, Sasane R, Gholizadeh S, Hodgkins P: Under diagnosis of adult ADHD: cultural influences and societal burden. J Atten Disord 2012, 16(5 Suppl):20S-38S.
• [32]Matheson L, Asherson P, Wong ICK, Clifford S: Adult ADHD Patients’ Experiences of Impairment, Accessing Services and Treatment Management - A Qualitative Study in England. 27th edition. Prague, Czech Republic: European Psychiatry; 2012:1. [20th European Congress of Psychiatry]
• [33]Service for the diagnosis and management of ADHD in adults. Commissioning and benchmarking tool. Implementing NICE guidance. http://www.nice.org.uk/media/242/86/ADHDAdultsCommissioningGuide.pdf webcite] [Accessed 21st June 2011